The efficacy of N-acetylcysteine in the treatment of methamphetamine dependence: A double-blind controlled, crossover study

Archives of Iranian Medicine

Volumn 18, Issue 1, 2015, Pages 28-33

  Mousavi, Seyed Ghafur ^a   Sharbafchi, Mohammad Reza ^a   Salehi, Mehrdad ^a   Peykanpour, Mohammad ^b   Sichani, Naeemeh Karimian ^c   Maracy, Mohammad ^d  

^a ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c UNIVERSITY OF ISFAHAN   (Iran)

^d ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Craving; Dependency; Methamphetamine; N acetylcysteine; Pharmacotherapy

Indexed keywords

ACETYLCYSTEINE; PLACEBO; CENTRAL STIMULANT AGENT; METHAMPHETAMINE; SCAVENGER;

ABDOMINAL CRAMP; ADULT; ARTICLE; CLINICAL ARTICLE; COCAINE CARVING QUESTIONNAIRE BRIEF; CONSTIPATION; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ELECTROCARDIOGRAPHY; FEMALE; HEADACHE; HUMAN; LIVER FUNCTION TEST; MALE; METHAMPHETAMINE DEPENDENCE; NAUSEA; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; WITHDRAWAL SYNDROME; XEROSTOMIA; DRUG ABUSE; QUESTIONNAIRE; SUBSTANCE WITHDRAWAL SYNDROME; TREATMENT OUTCOME; YOUNG ADULT;

ACETYLCYSTEINE; ADULT; AMPHETAMINE-RELATED DISORDERS; CENTRAL NERVOUS SYSTEM STIMULANTS; CRAVING; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; FREE RADICAL SCAVENGERS; HUMANS; MALE; METHAMPHETAMINE; QUESTIONNAIRES; SUBSTANCE WITHDRAWAL SYNDROME; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84920982748     PISSN: 10292977     EISSN: 17353947     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. United Nations Office on Drugs and Crime. World Drug Report 2010. United Nations Publications; New York, NY: 2010. Available from: URL: http://www.unodc.org/unodc/en/data-and-analysis/WDR-2010. html
2. Nguyen D, Smith LM, Lagasse LL, Derauf C, Grant P, Shah R, et al. Intrauterine growth of infants exposed to prenatal methamphetamine: results from the infant development, environment, and lifestyle study. JPediatr. 2010; 157: 337-339.
3. Davidson C, Gow AJ, Lee TH, Ellinwood EH. Methamphetamine neurotoxicity: Necrotic and apoptotic mechanisms and relevance to human abuse and treatment. Brain Res Brain Res Rev. 2001; 36: 1 22.
4. Nakagawa T, Kaneko S. Neuropsychotoxicity of abused drugs: molecular and neural mechanisms of neuropsychotoxicity induced by methamphetamine, 3, 4-methylenedioxymethamphetamine (ecstasy), and 5-methoxy-N,N-diisopropyltryptamine (foxy). J Pharmacol Sci. 2008; 106: 2-8.
5. Rawson RA, Marinelli-Casey P, Anglin MD, Dickow A, Frazier Y, Gallagher C, et al. A multi-site comparison of psychosocial approaches for the treatment of methamphetamine dependence. Addiction. 2004; 99(6): 708-717.
6. Lee NK, Rawson RA. A systematic review of cognitive and behavioural therapies for methamphetamine dependence. Drug Alcohol Rev. 2008; 27: 309-317.
7. Meredith CW, Jaffe C, Ang-Lee K, Saxon AJ. Implications of chronic methamphetamine use: A literature review. Harv Rev Psychiatry. 2005; 13: 141-154.
8. McCann UD, George A. Ricaurte. Amphetamine (or Amphetamine- like)-Related Disorders. In: Sadock BJ, Sadock VA, Ruiz P, editors. Kaplan & Sadock’s Comprehensive Textbook of Psychiatry. 9thed. New York: Lippincott Williams & Wilkins; 2009; 1289-1296.
9. Brackins T, Brahm NC, Kissack JC. Treatments for methamphetamine abuse: A literature review for the clinician. J Pharm Pract. 2011; 24(6): 541-550.
10. Grant JE, Odlaug BL, Kim SW. A double-blind, placebo-controlled study of N-acetyl cysteine plus naltrexone for methamphetamine dependence. EurNeuropsychopharmacol. 2010; 20(11): 823-828.
11. Anderson AL, Li SH, Biswas K, McSherry F, Holmes T, Iturriaga E, et al. Modafinil for the treatment of methamphetamine dependence. Drug Alcohol Depend 2012; 120(1-3): 135-141.
12. Li X, Malcolm RJ, Huebner K, Hanlon CA, Taylor JJ, Brady KT, et al. Low frequency repetitive transcranial magnetic stimulation of the left dorsolateral prefrontal cortex transiently increases cue-induced craving for methamphetamine: a preliminary study. DrugAlcohol Depend. 2013; 133(2): 641-646.
13. Kalivas PW, Lalumiere RT, Knackstedt L. Glutamate transmission in addiction. Neuropharmacology. 2009; 56: 169-173.
14. Baker DA, McFarland K, Lake RW, Shen H, Tang XC, Toda S, et al. Neuroadaptations in cystine-glutamate exchange underlie cocaine relapse. NatNeurosci. 2003; 6: 743-749.
15. LaRowe SD, Mardikian P, Malcolm R, Myrick H, Kalivas P, McFarland K, et al. Safety and tolerability of N-acetylcysteine in cocaine- dependent individuals. Am J Addict. 2006; 15: 105-110.
16. Grant, JE, Odlaug, BL, Kim, SW. A double-blind, placebo-controlled trial of a glutamate modulating agent, N-acetyl cysteine, in the treatment of trichotillomania. Arch Gen Psychiatry. 2009; 66 (7): 756-763. 23.
17. Copeland AL, Sorensen JL. Differences between methamphetamine users and cocaine users in treatment. Drug Alcohol Depend. 2001; 62(1): 91-95.
18. Cretzmeyer M, Sarrazin MV, Huber DL, Block RI, Hall JA. Treatment 24. of methamphetamine abuse: research findings and clinical directions. J Subst Abuse Treat. 2003; 24: 267-277.
19. LaRowe SD, Myrick H, Hedden S, Mardikian P, Saladin M, McRae A, et al. Is cocaine desire reduced by N-acetylcysteine? Am JPsychia- 25. try. 2007; 164: 1115-1117.
20. LaRowe SD, Kalivas PW, Nicholas JS, Randall PK, Mardikian PN, Malcolm RJ. A double-blind placebo-controlled trial ofN-acetylcysteine in the treatment of cocaine dependence. Am J Addict. 2013; 22(5): 26. 443-452.
21. First, MB, Spitzer, RL, Gibbon, M, Williams, JBW. Structured Clinical Interview for DSM-IV-Patient Edition (SCID-I/P, Version 2.0). Biometrics Research Department, New York State Psychiatric Insti- 27. tute, New York; 1995.
22. Sussner BD, Smelson DA, Rodrigues S, Kline A, Losonczy M, Ziedonis D. The validity and reliability of a brief measure of cocaine craving. Drug Alcohol Depend. 2006; 83(3): 233-237.
23. World Health Organization. Process of translation and adaptation of instruments. Available from: URL: http://www.who.int/substance:abuse/research_tools/translation/en/. (Accessed Date: 2013 Desember 11).
24. Mardikian PN, LaRowe SD, Hedden S, Kalivas PW, Malcolm RJ. An open-label trial of N-acetylcysteine for the treatment of cocaine dependence: a pilot study. Prog Neuropsychopharmacol Biol Psychiatry. 2007; 31: 389-394.
25. Amen SL, Piacentine LB, Ahmad ME, Li SJ, Mantsch JR, Risinger RC, et al. Repeated N-acetylcysteine reduces cocaine seeking in rodents and craving in cocaine-dependent humans. Neuropsychopharmacology. 2011; 36(4): 871-878.
26. Reichel CM, Moussawi K, Do PH, Kalivas PW, See RE. Chronic N-acetylcysteine during abstinence or extinction after cocaine selfadministration produces enduring reductions in drug seeking. J Pharmacol Exp Ther. 2011; 337(2): 487-493.
27. Zhou W, Kalivas PW. N-acetylcysteine reduces extinction responding and induces enduring reductions in cue- and heroin-induced drug- seeking. Biol Psychiatry. 2008; 63(3): 338-340.